Immutep (ASX:IMM) said its first-in-human phase 1 trial showed a favorable safety profile of its lead drug candidate IMP761 being developed for various autoimmune diseases, according to a Tuesday filing with the Australian bourse.
Results from the first three of a five single-dose ascending study showed no adverse events, with pharmacokinetic and pharmacodynamic relationship report slated for release in the first half of next year, the filing said.
The company's shares were down nearly 3% in recent Tuesday trade.
Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.94%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.